Core Laboratories N : Lab Announces Results of its 2020 Annual Shareholder Meeting

______________________________________________________________

FOR IMMEDIATE RELEASE

CORE LAB ANNOUNCES THE RESULTS OF ITS 2020 ANNUAL SHAREHOLDER MEETING

AMSTERDAM (20 May 2020) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext

Amsterdam: "CLB NA") announces it held its annual shareholder meeting on May 20, 2020 in Amsterdam, The Netherlands. At that meeting, the shareholders elected Mr. Harvey Klingensmith and Ms. Monique van Dijken Eeuwijk to the supervisory board and approved all agenda items. The vote results for all matters voted upon at the annual meeting of shareholders on May 20, 2020 are as follows:

Proposal No. 1 - Election of Class I Directors: The election of the Class I supervisory director was approved as follows:

Nominee		For		Withheld		Broker Non-Votes
Harvey Klingensmith	32,348,638	150,577	4,728,264
Monique van Dijken Eeuwijk	32,341,062	158,153	4,728,264

Proposal No. 2 - Appointment of KPMG as Independent Registered Public Accountant:The

appointment of KPMG as the independent registered public accountant for the year ending December 31, 2020 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
37,094,396	106,524	26,559		-

Proposal No. 3 - Confirm and Adopt the Dutch Statutory Annual Accounts: The confirmation

and adoption of the Company's Dutch Statutory Annual Accounts in the English language for the fiscal year ended December 31, 2019 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
37,120,816	74,895	31,768		-

1

Proposal No. 4 - Approve and Resolve the Cancellation of Repurchased Shares: The approval of the cancellation of the Company's repurchased shares held by the Company in its name at 12:01 a.m. CEST on May 20, 2020 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
37,081,788	111,640	34,051		-

Proposal No. 5 - Approve Extension - Repurchase up to 10% of Issued Share Capital: The approval of the extension of the existing authority to repurchase up to 10% of the Company's issued share capital from until November 20, 2021 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
36,512,522	662,734	52,223		-

Proposal No. 6 - Approve Extension to Issue Shares and/or Grant Rights: The approval of the extension of the authority to issue shares and/or to grant rights (including options to purchase) with respect to the Company's common and preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
36,895,931	286,176	45,372		-

Proposal No. 7 - Approve Extension to Limit or Exclude Preemptive Rights: The approval of the extension of the authority to limit or exclude the preemptive rights of the holders of the Company's common shares and/or preference shares up to a maximum of 10% of outstanding shares per annum until November 20, 2021 was approved as follows:

For		Against		Abstentions		Broker Non-Votes
36,941,201	214,491	71,787		-

2

Proposal No. 8a - Approve the Compensation of the Company's Executive Officers: The compensation program regarding the Company's named executive officers was approved, on an advisory basis, as follows:

For		Against		Abstentions		Broker Non-Votes
30,489,269	1,909,539	100,407	4,728,264

Proposal No. 8b - Cast a favorable advisory vote on the Remuneration Report for the Fiscal year ended December 31, 2019: The remuneration report was approved, on an advisory basis, as follows:

For		Against		Abstentions		Broker Non-Votes
30,485,938	1,903,502	109,775	4,728,264

Proposal No. 8c - Adopt the Remuneration Policy for the Management Board and the Supervisory Board in line with new Dutch legal requirements: The remuneration policy was approved, as follows:

For		Against		Abstentions		Broker Non-Votes
30,895,503	1,560,974	42,738	4,728,264

Proposal No. 9 - Approve and Resolve the Amendment and Restatement of the Core Laboratories 2014 Long-TermIncentive Plan ("LTIP"): The proposal regarding the LTIP was approved, as follows:

For		Against		Abstentions		Broker Non-Votes
30,980,658	1,480,684	37,873	4,728,264

For more information contact:

Gwen Y. Schreffler - SVP Corporate Development and Investor Relations, [phone] [e-mail]

# # # #

3